Inclusion Criteria:

- Pathologically proven gastric or gastroesophageal junction adenocarcinoma

- Metastatic or recurrent unresectable disease

- Measurable lesions (according to Response Evaluation Criteria in Solid Tumors
[RECIST])

- Age: 65-85 years old

- Performance status: Eastern Cooperative Oncology Group (ECOG) 0-2

- Adequate bone marrow function: absolute neutrophile counts(ANC) ≥ 1,500/ul, platelet
count ≥ 100,000/ul, hemoglobin ≥ 9 g/dl)

- Adequate renal function (serum creatinine≤ 1.5)

- Adequate liver function (serum bilirubin ≤ 2 x upper limits of normal [UNL],
aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3 x UNL)

- No prior chemotherapy (but adjuvant chemotherapy completed at least 1 year prior to
study treatment is allowed with the exception of capecitabine or S-1) Written
informed consent was signed by the patient

Exclusion Criteria:

- Previous palliative chemotherapy

- Known allergy to study drugs

- CNS metastasis

- Significant medical comorbidities

- Active ongoing infection which antibiotic treatment is needed.

- Previous ( within 5 years) history of other malignancy except cured non-malignant
skin cancer and uterine cervical cancer in situ.